Most of the peptides discussed in GLP-1 research today trace their design logic back to one molecule that nobody set out to find. It came from the venom of the Gila monster (Heloderma suspectum), a heavy, slow-moving lizard of the American Southwest and northern Mexico. This is the research-history version of that story. It is educational pharmacology, discussed strictly in a research-use-only context. Nothing here is medical, dosing, or usage guidance.
The problem with the native hormone
By the late 1980s, glucagon-like peptide-1 (GLP-1) was a known incretin hormone and an obvious target of study. It also had a practical flaw as a laboratory tool: it does not last. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the first two residues off the active hormone, and the native peptide is cleared within minutes. Any experiment that needed sustained receptor engagement was working against that clock.
A venom screen with an unusual filter
The answer came out of venom chemistry rather than hormone research. A team led by John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx, was looking for new members of the glucagon peptide family in lizard venoms. A related peptide, exendin-3, had already been identified in the venom of the Mexican beaded lizard (Heloderma horridum). Eng's group used an assay that picked out peptides starting with a histidine residue, a signature shared by the glucagon family, and applied it to Gila monster venom.
In 1992 they reported a 39-amino-acid peptide they named exendin-4. It differed from exendin-3 at just two positions near the N-terminus, and those two substitutions changed its activity in pancreatic tissue preparations.
The receptor connection
The following year, work by Göke and colleagues, with Eng as a co-author, showed that exendin-4 binds and activates the GLP-1 receptor on insulin-secreting cell lines, and that it competed with GLP-1 for the same binding site. Exendin-4 shares roughly half of its sequence with human GLP-1, but at the receptor it behaved as a full agonist.
The same paper characterized a truncated form, exendin-(9–39). With its first eight residues removed, the peptide still binds the GLP-1 receptor but no longer activates it. It became one of the standard GLP-1 receptor antagonists in research. For decades it has been the tool researchers reach for when they need to show that an effect in a model depends on GLP-1 receptor signaling.
Why the lizard peptide lasted
The key structural detail sits at position 2. In native GLP-1 that residue is alanine, which is exactly what DPP-4 recognizes. In exendin-4 it is glycine, and the enzyme largely fails to cut it. Exendin-4 was a GLP-1 receptor agonist that had, in effect, evolved its own protease resistance.
Exendin-4 did not need to be engineered to survive DPP-4. It arrived already resistant, and that showed chemists which part of the hormone needed protecting.
That observation shaped what came next. Later GLP-1 receptor agonists pursued the same goal by different routes. Semaglutide, for example, stays close to the human GLP-1 sequence but replaces the position-8 alanine (position 2 of the active hormone) with a non-natural amino acid, Aib, and adds a fatty-acid side chain for albumin binding. Synthetic exendin-4 itself, under the name exenatide, was approved by the FDA in 2005 as the first medicine in the GLP-1 receptor agonist class.
The tail that kept turning up
Exendin-4 has a C-terminal extension that human GLP-1 lacks, ending in the sequence PSSGAPPPS. Structural biologists found that this tail folds back against the peptide's helix and forms a compact, stable motif called a Trp-cage. The motif proved interesting enough that a trimmed-down version became a widely used model miniprotein in protein-folding research.
The same tail shows up in later incretin designs. Tirzepatide, a dual GIP and GLP-1 receptor agonist built on a GIP-derived backbone, ends in that exendin-4 sequence. The lizard peptide's influence runs through the multi-receptor compounds as well as the single-target ones.
Where the lineage goes from here
- Single-receptor GLP-1 agonists: semaglutide is the field's GLP-1-only reference compound. See Semaglutide vs Tirzepatide: A Research Comparison.
- Dual and triple agonists: tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon), covered in Retatrutide and the Triple-Agonist Era.
- Amylin pairings: cagrilintide extends the same design ideas to a different peptide hormone system. See Cagrilintide and the Amylin Comeback.
For the bigger picture, see GLP-1 Peptides in 2026: The Research Landscape. Venom pharmacology also has a longer track record than this one molecule: the ACE-inhibitor class began with peptides in pit viper venom, a story told in How Snake Venom Became a Blood-Pressure Drug.
Bench notes
The incretin-class peptides in our catalog are supplied lyophilized and must be reconstituted before laboratory use. Our free reconstitution calculator works out concentration from vial mass and diluent volume. Lot documentation is in the documentation library, and the full research catalog lists every available compound and configuration.
The takeaway
Exendin-4 is a reminder that a good research tool can come from anywhere. A venom peptide that evolved for a lizard's own purposes gave researchers a protease-resistant GLP-1 receptor agonist, a matching antagonist in exendin-(9–39), and a structural template that is still visible in compounds designed thirty years later. All compounds referenced here are offered strictly for research use only. They are not for human or veterinary use, and nothing in this article is medical advice or a recommendation of any kind.
Sources
Isolation of exendin-4 from Heloderma suspectum venom (39 residues; differs from exendin-3 at positions 2–3): Eng J, Kleinman WA, Singh L, Singh G, Raufman JP, Journal of Biological Chemistry, 1992;267(11):7402–7405 (doi:10.1016/S0021-9258(18)42531-8).
Exendin-4 as a GLP-1 receptor agonist, and truncated exendin-(9–39)-amide as an antagonist: Göke R et al., Journal of Biological Chemistry, 1993;268(26):19650–19655 (doi:10.1016/S0021-9258(19)36565-2).
These describe laboratory and animal pharmacology. Nothing in them, or here, is dosing guidance or a human claim.